Dishman Pharma standalone Q4 net profit rises 58%

Company declared equity dividend of 60% i.e. Rs 1.20 per share of Rs 2 each for the year 2012-13

Dishman Pharmaceuticals and Chemicals has posted a 58.7 per cent rise in net profit on a standalone basis for the quarter ended March 31, 2013 at Rs 39.82 crore, while net sales for the quarter grew by 10 per cent to Rs 162.10 crore from Rs 147.29 crore in the corresponding quarter last fiscal.

On a consolidated basis, however, the net profit dipped by 40.6 per cent to Rs 18.58 crore from Rs 31.29 crore in the corresponding period of last year mainly on the back of lower sales and higher input costs. Consolidated net sales moved down marginally by 1.4 per cent to Rs 345.46 crore from Rs 350.19 crore.

The company declared equity dividend of 60 per cent i.e. Rs 1.20 per share of Rs 2 each for the year 2012-13.

For the full year ended March 2013, Dishman has posted a 40.9 per cent rise in net profit on a standalone basis to Rs 63.17 crore from Rs 44.84 crore in the previous year. Dishman's net sales for the year ended March 2013 improved by 4.8 per cent to Rs 483 core from Rs 461 crore.

On a consolidated basis, Dishman posted a net profit growth of 77 per cent to Rs 100.29 crore from Rs 56.76 crore in the previous year on account of higher other income and lower raw material cost. Its consolidated net sales increased by 13 per cent to Rs 1,268 crore from Rs 1,122 crore and other income by 37.2 per cent to Rs 17.78 crore from Rs 12.96 crore. The raw material cost declined slightly to Rs 376 core from Rs 384 crore. The sales from contract research and manufacturing services (CRAMS) improved by 13.5 per cent to Rs 813 crore from Rs 716 crore and that from others increased by 12 per cent to Rs 454 crore from Rs 406 crore.